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Background: To compare the periodical incidence rates of genitourinary (GU) and gastrointestinal (GI) toxicity in
patients who underwent prostate low-dose-rate brachytherapy between the monotherapy group (seed
implantation alone) and the boost group (in combination with external beam radiation therapy (EBRT)).
Methods: A total of 218 patients with a median follow-up of 42.5 months were enrolled. The patients were divided
into 2 groups by treatment modality, namely, the monotherapy group (155 patients) and the boost group (63
patients). The periodical incidence rates of GU and GI toxicity were separately evaluated and compared between
the monotherapy group and the boost group using the National Cancer Institute - Common Terminology Criteria
for Adverse Events, version 3.0. To elucidate an independent factor among clinical and postdosimetric parameters
to predict grade 2 or higher GU and GI toxicity in the acute and late phases, univariate and multivariate logistic
regression analyses were carried out.
Results: Of all patients, 78.0% showed acute GU toxicity, and 7.8% showed acute GI toxicity, while 63.8% showed
late GU toxicity, and 21.1% showed late GI toxicity. The incidence rates of late GU and GI toxicity were significantly
higher in the boost group. Multivariate analysis showed that the International Prostate Symptom Score (IPSS) before
seed implantation was a significant parameter to predict acute GU toxicity, while there were no significant
predictive parameters for acute GI toxicity. On the other hand, combination with EBRT was a significant predictive
parameter for late GU toxicity, and rectal volume (mL) receiving 100% of the prescribed dose (R100) was a
significant predictive parameter for late GI toxicity.
Conclusions: The boost group showed higher incidence rates of both GU and GI toxicity. Higher IPSS before seed
implantation, combination with EBRT and a higher R100 were significant predictors for acute GU, late GU and late
GI toxicity.
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Low-dose-rate brachytherapy (LDR-brachytherapy) is a very
effective modality to administer a curative dose to the pros-
tate while avoiding unnecessary irradiation to the normal
surrounding tissues such as the urethra and rectum, espe-
cially in combination with external beam radiation therapy* Correspondence: sendo@naramed-u.ac.jp
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reproduction in any medium, provided the or(EBRT), because of the achievement of a high biological
effective dose (BED) [1]. On the other hand, genitour-
inary (GU) toxicity and gastrointestinal (GI) toxicity
are important distress factors associated with LDR-
brachytherapy. Many investigators have reported ad-
verse events after LDR-brachytherapy. Usually, adverse
events are evaluated in the acute and late phases using
the Radiation Therapy Oncology Group (RTOG) scale
[2-8] or the National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE) [9-13].
However, there have been few reports that refer toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients’ characteristics
Monotherapy Boost Total p value
(n = 155) (n = 63) (n = 218)
Age (year)
mean ± SD 68.1 ± 6.6 70.3 ± 6.2 68.7 ± 6.5 0.023 §
PSA at diagnosis
(ng/mL)
mean ± SD 7.2 ± 2.4 12.5 ± 6.1 8.7 ± 4.5 < 0.001 §
10 or less 139 22 161
10-20 16 34 50
greater than 20 0 7 7 < 0.001 ※
biopsy Gleason
score
6 or less 111 22 133
7 44 32 76
8-10 0 9 9 < 0.001 ※
clinical T stage
T1c 99 32 131
T2a 51 19 70
T2b 5 6 11
T2c 0 6 6 < 0.001 ※
neoadjuvant/adjuvant
ADT
none 112 37 149
neoadjuvant (+) 42 18 60
adjuvant (+) 0 5 5
both 1 3 4 0.001 ※
IPSS at baseline
mean ± SD 8.7 ± 6.9 7.2 ± 5.6 8.3 ± 6.6 0.107 §
Follow-up period
(month)
mean ± SD 44.2 ± 14.9 38.3 ± 16.2 42.5 ± 15.5 0.011 §
※ Chi-square test and § t-test.
Table 2 Postdosimetric parameters (all patients: n = 218)
Monotherapy Boost P value
(n = 155) (n = 63) (t-test)
PV (mL) at postdosimetry 27.8 ± 8.3 27.2 ± 9.4 0.660
%D90 (%) 109.4 ± 9.7 113.7 ± 9.1 0.002
D90 (Gy) 164.7 ± 16.6 125.1 ± 10.0 < 0.001
V100 (%) 93.3 ± 3.8 94.8 ± 2.8 0.005
V150 (%) 61.5 ± 9.9 64.9 ± 11.0 0.029
UD30 (Gy) 211.1 ± 28.5 156.0 ± 20.1 < 0.001
%UD30 (%) 140.9 ± 19.0 141.7 ± 18.6 0.784
R100 (mL) 0.08 ± 0.16 0.11 ± 0.19 0.349
%RD30 (%) 26.1 ± 8.1 27.2 ± 7.4 0.330
RD30 (Gy) 39.9 ± 11.0 30.3 ± 7.4 < 0.001
BED (Gy2) 174.3 ± 18.4 216.1 ± 23.2 < 0.001
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brachytherapy [7].
In this study, we evaluated the GU and GI toxicity in
patients who underwent LDR-brachytherapy, not only in
the acute and late phases, but also in each period after
seed implantation using the NCI-CTCAE. We also com-
pared the incidence rates of GU and GI toxicity in the
monotherapy group (seed implantation alone) with those
in the boost group (combination of external beam radi-
ation therapy). To our best knowledge, this is the first
study designed to assess the periodical incidence rates of
both GU and GI toxicity in patients who underwent
prostate LDR-brachytherapy.
Methods
A total of 218 patients who were clinically diagnosed
with localized prostate cancer (cT1c-2cN0M0) and who
underwent LDR-brachytherapy between July 2004 and
November 2008 were enrolled in this prospective study.
The patients’ characteristics are shown in Table 1. The
median age, PSA value at diagnosis, and follow-up
period were 68.7 years (range: 51–80), 8.7 ng/mL
(range: 3.1-32.1), and 42.5 months (range: 1–72), respect-
ively. A single pathologist (K.N) with expertise in prostate
cancer diagnosis reviewed the Gleason score of all biopsy
specimens centrally. GU and GI toxicity were evaluated
using the National Cancer Institute - Common Termin-
ology Criteria for Adverse Events, version 3.0 (CTCAE
ver.3.0) at 1, 3, and 6 months after seed implantation, and
every 6 months thereafter. The incidence rates of each
adverse event at 1 to 5 months, 6 to 12 months, 13 to
24 months, 25 to 36 months, and 37 to 48 months
were separately calculated according to CTCAE ver.
3.0 grading, and were compared between the mono-
therapy group and the boost group. This study was per-
formed in compliance with the Helsinki Declaration. The
institutional reviewer board approved this prospective
study, and informed consent was obtained from all patients
after explaining the aim and methods of this study.
Treatment
Of all the patients, 149 did not receive neoadjuvant or ad-
juvant androgen deprivation therapy (ADT), 4 received
both neoadjuvant and adjuvant ADT, 60 received only
neoadjuvant ADT, and 5 received only adjuvant ADT. The
study treatment was seed implantation alone in 155
patients (monotherapy group), whereas 63 patients were
treated with seed implantation in combination with EBRT
(boost group) (Table 1).
From July 2004 to April 2007, there were 97 patients
who were treated with seed implantation at a prescribed
dose of 145 Gy, and 58 patients were treated at a pre-
scribed dose of 160 Gy after May 2007. The prescribed
dose was 110 Gy for the patients who received seed
Table 3 GU and GI toxicity in all patients
Grade 0 Grade 1 Grade 2 Grade 3
GU (acute) 48 (22.0) 157 (72.0) 10 (4.6) 3 (1.4)
GU (late) 79 (36.2) 112 (51.4) 25 (11.5) 2 (0.9)
GI (acute) 201 (92.2) 16 (7.3) 1 (0.5) 0
GI (late) 172 (78.9) 40 (18.3) 6 (2.8) 0
NCI-CTCAE (ver. 3.0) (%)
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tion of EBRT was determined one month after seed im-
plantation, and the patients received 45 Gy (in 25 fractions
of 1.8 Gy per fraction) using a four-field box technique
with 6–10 MV photon energy. The clinical target volume
included both the whole prostate and a third of the prox-
imal seminal vesicle.
From July 2004 to April 2007, seed implantation was
performed after preplanning by modified peripheral
loading techniques using a Mick’s applicator [14]. From
May 2007 to October 2008, we introduced an intrao-
perative planning method, and thereafter we used a real-
time planning technique and a peripheral loading
technique.
Postdosimetric evaluation
Therapeutic planning and post-implant dosimetric evalu-
ation were performed using the planning system Inter-
plant Version 3.3 (CMS, Inc., St. Louis, USA) from July
2004 to October 2008, and Variseed 8.0 (Varian Medical
Systems, Palo Alto, CA, USA) thereafter.
Post-implant CT scanning and post-implant dosimetric
study was performed by a single radiation oncologist (A.I)
at 1 month after seed implantation. The dosimetric para-
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Figure 1 The incidence rates of both acute and late GU and GI toxicitof the dose received by 90% of the prostate gland (%D90),
minimal dose (Gy) received by 90% of the prostate gland
(D90), percentage of the prostate volume receiving 100%
and 150% of the prescribed minimal peripheral dose
(V100/150), minimal percentage of the dose and minimal
dose (Gy) received by 30% of the urethra (%UD30 and
UD30), rectal volume (mL) receiving 100% of the pre-
scribed dose (R100), minimal percentage of the dose and
minimal dose (Gy) received by 30% of the rectum (%RD30
and RD30),and biologically effective dose (BED). BED was
calculated to evaluate an independent factor to predict
GU and GI toxicity, and an α/β ratio of 2 was used [1].
Statistic analysis
To elucidate independent factors to predict grade 2 or
higher GU and GI toxicity in the acute and late phases,
the prostate volume at postdosimetry, %D90, D90, V100,
V150, UD30, %UD30, R100, %RD30, RD30, BED, use of
neoadjuvant ADT, adjuvant ADT, International Prostate
Symptom Score (IPSS), treatment modality (monother-
apy vs. boost), and prescribed dose (145 Gy, 160 Gy, or
110 Gy) were evaluated.
In this study, acute toxicity was defined as toxicity that
occurred < 6 months after seed implantation and late
toxicity as toxicity that occurred after 6 months or later.
The t-test was used to compare continuous variables,
and the chi-square test for categorical variables.
The chi-square test was also used to test the difference
in the incidence of adverse events between the mono-
therapy group and the boost group at each visit. Both
univariate and multivariate logistic regression analyses
(stepwise selection method) were conducted to discrimin-
ate the predictive parameters of grade 2 or higher GU and
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Figure 2 The periodical incidence rates of hematuria.
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0.10) were input into multivariate models. All statistical
analyses were performed using PASW Statistics 17.0
(SPSS Inc., Chicago, IL, USA). All p values below 0.05
were considered statistically significant.
Results
PSA at diagnosis, biopsy Gleason score, and clinical
stage in the monotherapy group were significantly higher
than those in the boost group, while patients’ age in the
monotherapy group was significantly younger than that
in the boost group. A higher proportion of patients in
the boost group received androgen deprivation therapy
compared with the monotherapy group. There were no
significant differences in the baseline IPSS between the
monotherapy group and the boost group. The mean
follow-up period in the monotherapy group was signifi-



















Figure 3 The periodical incidence rates of miction pain.Regarding the postdosimetric parameters, %D90, V100,
V150, and BED in the boost group were significantly
higher than those in the monotherapy group, while
UD30 and D90 (Gy) of the boost group was significantly
lower than that in the monotherapy group (Table 2).
Of all patients, 78.0% showed grade 1 or higher acute
GU toxicity, 7.8% showed grade 1 or higher acute GI
toxicity, 63.8% showed grade 1 or higher late GU tox-
icity, and 21.1% showed grade 1 or higher late GI tox-
icity (Table 3).
Figure 1 shows a comparison of GU and GI toxicity
between the monotherapy group and the boost group in
both the acute and late phases. There were no significant
differences in acute GU and GI toxicity between the two
groups, while late GU and GI toxicity were significantly
higher in the boost group.
Figures 2, 3, 4, 5, 6, 7 and 8 shows the results of each
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Figure 4 The periodical incidence rates of urinary incontinence.
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urgency, urinary retention, proctitis, and rectal bleeding.
Severe complications were infrequent, most complica-
tions were G2 or lower, except for urinary retention.
There were several patients who developed G3 urinary re-
tention in the monotherapy group. Overall, 8 of all the
patients developed acute urinary retention during the
follow-up period. Six of these 8 patients developed acute
urinary retention within 1 month after seed implantation,
and the other 2 developed it at 42 and 53 months after seed
implantation, respectively. The incidence rates of urinary
incontinence, urinary frequency/urgency rectal bleeding
and proctitis in the boost group were significantly higher
than those in the monotherapy group.
To elucidate the predictive parameters for GU and GI
toxicity, univariate and multivariate logistic regression
analyses were carried out (Table 4). IPSS before seed im-























Figure 5 The periodical incidence rates of urinary frequency/urgencyparameters for acute GU toxicity in the univariate ana-
lysis. In the multivariate analysis, IPSS before seed im-
plantation was a significant predictive parameter for
acute GU toxicity, and there was no significant predict-
ive parameter for acute GI toxicity. On the other hand,
BED, %D90, V100 and combination with EBRT remained
predictive parameters for late GU toxicity in the univariate
analysis. Finally, combination with EBRT remained in the
multivariate analysis. Regarding late GI toxicity, BED,
R100, %RD 30 and combination with EBRT remained in
the univariate analysis. Finally, R100 remained in the multi-
variate analysis.
Discussion
Many investigators [2-14] have reported adverse events
after LDR-brachytherapy. In some studies the adverse
events were assessed by the RTOG or RTOG/EORTC scale
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Figure 6 The periodical incidence rates of urinary retention.
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in tetrameric style. To our best knowledge, this is the first
study designed to assess the periodical incidence rates of
both GU and GI toxicity in patients who had undergone
prostate LDR-brachytherapy. Overall, severe adverse events
were infrequent in the present study population. Only 6
patients developed grade 3 toxicity (3 patients: acute GU, 3
patients: late GU). No patients developed grade 3 GI tox-
icity. Stratified by treatment modality, the boost group
showed significantly higher incidence rates of late GU and
GI toxicity compared with the monotherapy group. On the
other hand, there were no significant differences in acute
GU and GI toxicity between the two groups.
In particular, acute GU toxicity was well observed in
both the monotherapy group and the boost group.
Around 80% of patients showed acute GU toxicity. This
is comparable to the previous reports [5,7,10,11]. Our




















Figure 7 The periodical incidence rates of proctitis.parameter (uroflowmetry) and a subjective parameter
(IPSS) showed transient deterioration in the first
6 months after seed implantation [15]. There were no
significant differences between the two groups. However,
the grade of toxicity was low, and most patients had
grade 1. On the other hand, acute GI toxicity was not
frequently observed in either group, as was previously
reported [5,9,11].
To see the details of the GU and GI toxicities in each
follow-up period, there were no significant differences in
the incidence rates of hematuria, urinary retention be-
tween the monotherapy and the boost groups (Figures 2,
3, 6), but the incidence rates of urinary incontinence,
urinary frequency/urgency, proctitis and rectal bleeding
were significantly higher in the boost group than in the
monotherapy group (Figures 4, 5, 7, 8). In particular, rec-
tal bleeding and proctitis were often observed in the
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Figure 8 The periodical incidence rates of rectal bleeding.
Table 4 The univariate and multivariate analyses in
predicting acute GU, late GU and late GI toxicity of grade
2 or greater in all patients
Univariate Multivariate
P value P value OR 95% C.I.
Acute GU




BED (Gy2) 0.020 n.s.
%D90 (%) 0.069 n.s.
V100 (%) 0.088 n.s.
EBRT no reference
yes 0.022 0.022 2.619 1.152–5.951
Late GI
BED (Gy2) 0.049 n.s.
R100 (mL) 0.02 0.034 16.626 1.235–223.837
%RD30 (%) 0.039 n.s.
EBRT no reference
yes 0.061 n.s.
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groups (Table 2). It can however easily be conceived that
the total dose to the rectum must be higher in the boost
group. Indeed, Snyder et al. reported that the risk of
developing grade 2 proctitis was significantly associated
with the rectal volume (cut-off value: 1.3 mL) receiving
the prescribed dose (160 Gy) [2]. Zelefsky also reported
similar results [9]. Ohashi et al. also reported that the
predictive parameter of grade 2 or higher GI toxicity
was the maximal rectal dose in multivariate analysis
[4]. Aoki et al. concluded that R150 was a significant
prognostic factor for rectal bleeding in multivariate
analysis [6].
In our present study, IPSS was the only prognostic fac-
tor predicting grade 2 or higher acute GU toxicity in
multivariate analysis. Zelefsky et al. had similarly con-
cluded that treatment modality (implant alone vs. com-
bined modality) and IPSS were significant predictors of
the incidence of acute grade 2 toxicities by CTCAE grad-
ing [11]. Keyes et al. also reported that the IPSS was the
most significant factor by the RTOG score [7]. On the
other hand, there were no significant factors predicting
grade 2 or higher acute GI toxicity in our study, because
there were only a few patients who developed grade 2 or
higher acute GI toxicity. Meanwhile, our present study
demonstrated that combination with EBRT was a predict-
ive factor for late GU toxicity. The only predictive factor
for late GI toxicity in our present study was R100. This re-
sult was comparable to previous reports [6,8,9,11].
There were several limitations in the present study
such as a small number of patients (n = 218), a medium
follow-up period (42.5 months), a heterogeneous patient
population, etc. However, we believe that it is meaning-
ful to assess the periodical incidence rates of both GU
and GI toxicity in detail to elucidate the time course
changes of urinary and rectal morbidity after seedimplantation, because most previous reports had merely
evaluated acute and late GU and GI toxicity in acute
and late phases.
Conclusions
The incidence rates of GU and GI toxicity were signifi-
cantly different between patients in the monotherapy
and the boost groups. The boost group showed a higher
incidence rate, especially of GI toxicity. Patients with a
higher IPSS before seed implantation showed a higher
incidence rate of acute GU toxicity, while patients
Tanaka et al. Radiation Oncology 2013, 8:25 Page 8 of 8
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GU toxicity. Regarding late GI toxicity, R100 was a sig-
nificant parameter
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